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Background: E2A gene, which encodes two basic helix–loop–helix (bHLH) transcription factors E12 and E47, has
been identified as regulator of B lymphoid hematopoiesis and suppressor of lymphoma. E47 protein was found to
decrease E-cadherin expression and induce epithelial-mesenchymal transition (EMT). However, the role of E2A in
colorectal cancer (CRC) metastasis is still elusive.
Methods: qRT-PCR and semi-qRT-PCR were performed to determine mRNA level of E2A in CRC specimens and
colorectal cancer cells. RNAi was employed to downregulate E2A expression and subsequent protein level change
was evaluated by immunoblot. Cell invasion and migration capacity were detected by transwell assay using cell
culture inserts with or without basement membrane matrix, respectively.
Results: E2A expression was decreased in metastatic CRC tissues. Invasion and migration assays showed
downregulation of E2A increased metastatic capacity of CRC cells while forced expression of E12 or E47 could
offset this effect. Both E12 and E47 suppressed EMT induced by E2A downregulation. Moreover, Yes-Associated
Protein (YAP) was a downstream target of E2A and suppression of YAP inhibited the pro-migration/invasion of
E2A deficiency.
Conclusion: Our results suggest that E2A suppresses CRC cell metastasis, at least partially if not all, by inhibiting
YAP expression.
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Colorectal cancer (CRC) is one of the most prevalent
malignancies worldwide, ranking the third of all cancer-
related deaths, and distant metastasis is the major cause of
deaths for CRC patients [1]. These secondary tumors arise
as the result of a multi-step process which begins when
cancer cells within primary tumors break away from the
microenvironment and invade through the basement
membrane [2]. Although many metastasis-related genes
have been identified in CRC [3], the complicated mole-
cular mechanism of CRC development and progression is
not yet fully understood.* Correspondence: zhihai.mao@gmail.com; davisd0zhao@hotmail.com
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stated.The E2A gene encodes two basic helix–loop–helix
(bHLH) transcription factors, E12 and E47, by means of
variant splicing [4]. The E2A proteins (E12/E47) belong
to the class I bHLH family and regulate expression of
target genes by binding DNA with tissue-specific Class
II HLH proteins, either as homodimers or as heterodi-
mers [5-7]. Previous studies have shown that E12/E47
proteins are distributed widely in most adult tissues
although at different expression levels [8,9]. Both proteins
are indispensable for some normal tissue development
while deficiency or aberrant expression of E2A could lead
to tumorigenesis. For instance, E12/E47 proteins are
required for B-cell differentiation and Ig gene rearrange-
ments [10]; two aberrant fusion proteins, E2A-HLF and
E2A-PBX1, lead to pro-B cell acute lymphoblastic leuke-
mia (ALL) and pre-B cell ALL [11]. In addition, targeted
disruption of the E2A gene leads to thymic lymphomas,
suggesting that E2A gene products can act as tumortd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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lial maker E-cadherin was repressed upon E12/E47 bind-
ing to the E-pal element, a palindromic sequence between
−75 and −86 in the E-cadherin promoter [14].
In colorectal cancer, ectopic expression of the E47
efficiently sequestered endogenous Id proteins from
Id-bHLH heterodimers, leading to growth arrest of
the cells [15]. However, it still remains unknown
whether E12/E47 proteins affect CRC cells metastasis
or not. In the present study, we demonstrated that
E2A down-regulation was required for the develop-
ment of metastasis while ectopic expression of E2A in
CRC cells could suppress invasion and migration
in vitro. Furthermore, we identified, and validated




Human colorectal cancer cell lines, SW480 and Caco-2,
were purchased from American Type Culture Collection
(ATCC). SW480 was cultured in Leibovitz’ L-15 Medium
(Corning Cellgro®, Manassas, VA, USA) with 10% fetal
bovine serum (FBS) (Invitrogen, Carlsbad, CA, USA), and
Caco-2 in Minimum Essential Medium (Corning Cellgro®)
with 20% FBS. Cells were maintained at 37°C/5% CO2 in a
humidified incubator.
Clinical specimens
The clinical research protocol was approved by the
Ethical Committee of Ruijin Hospital, Shanghai Jiao
Tong University School of Medicine. Seventy-five surgical
specimens of primary CRC tumors were obtained from
Shanghai Minimal Invasive Surgery Center (2012–2013)
with written informed consents given by all patients prior
to surgery. Inclusion criteria were: without neoadjuvant
chemoradiotherapy; resectable colorectal cancers; without
evidences of primary tumors of other organs; able to be
interviewed during the follow-up. Fresh tumor tissues
were harvested immediately after samples’ dissection,
snap-frozen in liquid nitrogen, and preserved at −80°C.
The pathologic classification/staging of tumors was
performed in accordance to the Cancer Staging Manual
from the International Union Against Cancer (7th edition,
2009). Tumor samples were classified into two groups:
tumors with metastatic sites and tumors without meta-
stases, based on the status of lymph node and/or distant
metastasis.
Protein extraction and immunoblot
RIPA buffer (Solarbio, Beijing, China) containing prote-
ase inhibitor cocktail (Roche Applied Science, Basel,
Switzerland) was used to extract total tissue and cell pro-
teins, according to manufacturer’s instruction. Immunoblotwas done according to the standard protocol, with pri-
mary antibodies against E2A (Santa Cruz, Dallas, Texas,
USA), vimentin (Santa Cruz), E-cadherin (Cell Signaling
Technol., Danvers, MA, USA), β-catenin (Cell Signaling
Technol.), YAP (Cell Signaling Technol.) and MMP-9
(Cell Signaling Technol.). Goat anti-mouse or goat anti-
rabbit IgG conjugated to horseradish peroxidase (HRP,
Pierce, Rockford, IL, USA) was used as the secondary
antibody. Chemiluminescent signals were visualized using
SuperSignal West Pico Chemiluminescent Substrate
(Pierce) and the signal intensity was analyzed using the
Image Lab™ Software Version 4.0.1 (BIO-RAD, Hercules,
CA, USA). The experiments were performed in triplicate
with GAPDH (Kangchen, Shanghai, China) as endogenous
control.
Immunofluorescence
Cells growing on slides (Millipore, Billerica, MA, USA)
were fixed with 4% paraformaldehyde (PFA, Sigma-
Aldrich, St.Louis, USA) and permeabilized for 10 min
using 0.1% TritonX-100/phosphate buffered saline (PBS).
Non-specific antigens were then blocked with 3% BSA
in PBS-T (0.2% Tween 20) for 1 h at room temperature.
After washing, cells were incubated with primary anti-
bodies against vimentin (Santa Cruz), E-cadherin (Cell
Signaling Technol.), β-catenin (Cell Signaling Technol.)
in 4°C overnight, followed by incubation with Alex
Fluor® 555 anti-Rabbit IgG (Cell Signaling Technol.) for
2 hours at room temperature. Images were examined
and captured using an Olympus Fluoview Confocal
Microscope. Rabbit mAb IgG XP isotype (Cell Signaling
Technol.) was used as negative control.
Invasion and migration assay
Cell invasion and migration assays were performed using
cell culture inserts (Millipore) coated with or without
basement membrane matrix (BD Bioscience, Bedford,
MA, USA), respectively. Assays were performed as
previously described [16,17]. In brief, approximate 1 × 105
cells resuspended in 200 μl non-serum culture medium
were placed triplicatedly in upper chamber of insert and
medium with 10% FBS was used as chemo-attractant in
lower chamber; inserts were incubated at 37°C for
48 hours in a 5% CO2 humidified incubator. Cells attached
on the inner side of the chamber were then cleared softly
with cotton swab and cells outside the insert were stained
in 1% crystal violet for 30 minutes. Cells in five random
fields were counted under microscope and the relative
invasion and migration capacity were interpreted as the
average number of cells ± SD per field.
RNA extraction and RT-PCR
Total RNAs from cell lines and tissues were extracted using
Trizol reagent (Invitrogen) according to the manufacturer’s
Figure 1 Expression of E2A is decreased in metastatic CRCs.
A, Relative E2A mRNA expression in primary CRCs with or without
metastasis. The levels of E2A mRNA were examined using qRT-PCR
by the 2-ΔCT method with GAPDH mRNA as internal control. B, E2A
protein expression in primary CRCs with or without metastasis was
detected with immunoblot using GAPDH protein as loading control.
Protein samples of lane 1, 3, 5, 7, 9 and 11 were from tumors
without metastasis, while lane 2, 4, 6, 8, 10 and 12 were from tumors
with metastasis. Samples were selected and paired randomly.
Data represents means ± SD from 3 independent experiments.
**, P < 0.01.
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using GoScript™ Reverse Transcriptase System (Promega,
Madison, WI, USA) as per protocol. The mRNA level of
YAP (forward: 5′- TAGCCC TGCGTAGCCA GTTA -3′;
reverse: 5′- TCATGC TTAGT CCACTGTCTGT -3′) in
cell lines was assessed by semi-qRT-PCR using Taq PCR
MasterMix (Tiangen, Beijing, China). GAPDH (forward:
5′-GGAGC GAGAT CCCTC CAAAAT-3′; reverse: 5′-
GGCTG TTGTC ATACT TCTCA TGG-3′) was used as
an internal loading control. The expression of E2A
(forward: 5′- CCACTT CACTG AGTCGC ACAG -3′;
reverse: 5′- GTCTCT CCCGAA GGAGG CATA -3′) and
YAP in tumor tissues were detected by real-time qRT-
PCR using SYBR Green PCR Master Mix (Invitrogen) on
the Applied Biosystems 7900HT sequence detection
system with GAPDH as endogenous control.
Transient transfection
Short hairpin RNA (shRNA) against human YAP and
shRNA negative control (shNC) were bought from Gene-
Pharma (Shanghai, China). Plasmids pEZ-M29-E12 and
pEZ-M29-E47, encoding fusion protein of eGFP-E12 or
eGFP-E47 respectively, were purchased from Genecopoeia
(Rockville, MD, USA). Cells were seeded in 6-well culture
plates one day before transient transfection, which was
performed with lipofectamine 2000 (Invitrogen), accord-
ing to the instruction of manufacturer. Forty-eight hours
after transfection, cells were harvested and the protein
levels of the targeted genes were assessed by immunoblot,
with GAPDH as loading control.
Lentiviral transfection for stable expression clones
Plasmids pL/shRNA/F-shR with shE2A or shNC (negative
control), namely LV-shE2A and LV-shNC, were purchased
from Novobio (Shanghai, China). Lentivirus transfection
was performed according to the manufacturer’s instruc-
tion to establish shE2A-expressing stable clones in SW480
cells (SW480/shE2A). The control clone (SW480/shNC)
was constructed similarly. E2A protein expressions of
abovementioned clones were examined by immunoblot
using GAPDH as loading control.
Statistical analysis
Two-tailed Student’s t-test, Spearman’s correlation or
one-way ANOVA were used for statistical analysis when
appropriate. All statistical analyses were performed using
the SPSS 16.0 (SPSS Inc., Chicago, IL, USA). A two-
tailed value of p < 0.05 was considered statistically
significant.
Results
Expression of E2A was decreased in metastatic CRCs
To determine the role of E2A in CRC metastasis, we
evaluated the mRNA expression level of E2A in 75clinical specimens using qRT-PCR. Of the 75 cases, 43
patients were male and 32 were female with a median
age of 56 years (range: 41–76 years); besides, 41 cases
were metastasis negative and 34 were positive (including
pathology confirmed lymph node and CT-scan detected
distant metastases). As shown in Figure 1A, E2A mRNA
expression was significantly decreased in tumors with
metastases compared to those without (p < 0.01). We
then made a correlation analysis to detect the relation-
ship between E2A expression and clinicalpathological
variables by classifying patients into E2A low or high
group using the median E2A expression level as cutoff
value. As shown in Table 1, expression of E2A was not
related to gender (p = 0.653), age (p = 0.272), tumor hist-
ology (p = 0.410), or tumor site (p = 0.874), but inversely
associated with advanced TNM stage (p = 0.010).
To further confirm that E2A was also down-regulated
at protein level in tumors with metastases, immunoblot
was performed using 6 metastatic and 6 non-metastatic
tumors chosen randomly from each group. As demon-
strated in Figure 1B, metastatic tumors showed lower
expression level of E2A protein. Taken together, lower
E2A expression associates with positive metastatic status
in CRCs.
Table 1 Relationship between E2A expression level and
clinicopathologic variables in CRC patients
Variables Subgroup E2A expression P value
Low High
Gender Male 26 17 0.653
Female 21 11
Age (years) <60 22 15 0.272
≧60 25 13
Tumor histology Tubular 39 21 0.410
Mucinous 8 7
Tumor site Rectum and sigmoid 31 18 0.874
Right colon 11 7
Left colon 5 3




Metastasis Negative 21 20 0.024
Positive 26 8
Figure 2 E2A suppresses CRC cells invasion and migration. A, Effect of
reduced in shE2A treated SW480 cells compared to blank and shNC treated
mRNA expression of shE2A-, shNC-treated and Blank SW480 cells. B, Transfe
and proteins expression. C, Downregualtion of E2A increased invasion and
expression suppressed invasion and migration abilities of SW480/shE2A cel
magnification of 100×. Scale bars: 100 μm Data represents the means ± SD
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Next we wanted to know whether E2A was involved in
regulation of CRC metastasis. To this end, SW480 cells
were transfected with LV-shE2A to establish SW480/
shE2A stable clones and LV-shNC was used as control.
Transfection efficacy was verified by immunoblot and
qRT-PCR (Figure 2A). Then we conducted cell invasion
and migration assays. As shown in Figure 2B, down-
regulation of E2A increased the invasion and migration
ability of SW480 cells by ~1.2 folds compared with the
blank and shNC groups (p < 0.01). Given that E2A has
two transcriptional variants E12 and E47, we went a step
further by transiently transfecting SW480/shE2A cells
with either pEZ-M29-E12 or pEZ-M29-E47 to ectopi-
cally express E12 or E47 to discover the isoform respon-
sible for the suppression effect. The transfection efficacy
was validated by immunoblot and qRT-PCR (Figure 2C).
As demonstrated in Figure 2D, both E12 and E47
reduced invasion and migration of SW480/shE2A cells
(p < 0.01); importantly, no significant differences in sup-
pression effect between E12 and E47 were observed.
Then we used another colorectal cancer cell line,
Caco-2, to investigate whether E2A exerted its functionshE2A on E2A expression. Left panel: Immunoblot showed E2A was
ones. GAPDH was used as loading control. Right panel: Relative E2A
ction of plasmids pEZ-M29-E12 and pEZ-M29-E47 increased E2A mRNA
migration abilities of SW480 cells. D, Forced ectopic E12 or E47
ls. Representative photos of stained cells are shown with the original
from 3 independent experiments. *, P < 0.05; **, P < 0.01.
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two stable clones, Caco-2/shE2A (expressing shE2A)
and Caco-2/shNC (expressing negative control) and as
observed in SW480 cells, metastasis ability of Caco-2
cells increased upon shE2A transfection and was sup-
pressed by E12 and E47 (Additional file 1: Figure S1A & B),
suggesting the metastasis suppression effect of E2A was
not cell line dependent. Hence, E2A was a metastasis
suppressor gene in CRC.
E2A inhibited the EMT program
In recent years, EMT has gained more attentions due to
its importance in the acquisition metastatic potential
during cancer progression [18-20]. Given the fact that
E2A was decreased in metastatic CRCs and knockdown
of E2A in CRC cells could promote invasion and migra-
tion, we wanted to know whether E2A could regulateFigure 3 E2A expression inhibits EMT in CRC cells. A, Knockdown of E2
lysis showed epithelial marker E-cadherin was decreased and mesenchyma
SW480 clone, indicating induction of EMT. MMP-9 was also increased upon
GAPDH was used as loading control. Right panel: Densitometric analysis of
suppressed EMT and MMP-9 expression. Left penal: Immunoblot analysis o
or without transfection of E12 or E47. Right penal: Densitometric analysis o
means ± SD from 3 separate experiments. C, Immunofluorescence analysis
Nuclei were counterstained with 4′, 6-diamidino-2-phenylindole (DAPI). MaEMT program in CRC cells. Indeed, expression of the
epithelial marker E-cadherin was decreased and the
mesenchymal markers vimentin and β-catenin were in-
creased in SW480/shE2A cells (Figure 3A). In consistent
with increased invasion ability, the expression of matrix
metalloproteinases 9 (MMP-9) was elevated after down-
regulation of E2A (Figure 3A). Similarly, we transfected
E12 and E47 plasmids separately into SW480/shE2A
cells to identify which one was responsible for EMT
regulation. As shown in Figure 3B, both E12 and E47
suppressed the transition induced by shE2A, with
vimentin and β-catenin both reduced about fifty per-
cent and E-cadherin enhanced by ~2 folds. Moreover,
expression of these EMT makers didn’t show signifi-
cant differences between E12- and E47-transfected
SW480/shE2A cells (p > 0.05). Also, MMP-9 decreased
after E12 and E47 transfection (Figure 3B).A induced EMT and MMP-9 expression. Left panel: Immunoblot ana-
l markers vimentin and β-catenin were increased in shE2A-expressing
E2A downregulation, which demonstrated enhanced invasion ability.
left panel normalized to GAPDH. B, Expression of E12 and E47
f E-cadherin, vimentin, β-catenin, MMP-9 and GAPDH expression with
f left normalized to GAPDH. Data in the histograms is expressed as the
using anti- E-cadherin, vimentin, β-catenin antibodies as indicated.
gnification: 400×; Scale: 50 μm. *, P < 0.05; **, P < 0.01.
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gram regulation, we performed immunofluorescence to
visualize these EMT markers in transfected SW480 cells.
In coincidence with immunoblot results, immunofluor-
escence showed that E-cadherin was significantly de-
creased while vimentin and β-catenin were increased in
SW480/shE2A cells compared with SW480 and SW480/
shNC cells (Figure 3C). Furthermore, both E12 and E47
restored the expression of E-cadherin in SW480/shE2A
cells while suppressed vimentin and β-catenin (Figure 3C).
Thus, E2A may suppress invasion and migration through
inhibiting EMT in CRC.
YAP was a downstream target through which E2A
suppressed metastasis
The findings above further led us to explore the
potential molecules with which E2A interacted to
regulate metastasis in CRC. As we described later, YAP
(Yes-Associated Protein) was found to be one down-
stream target. We detected YAP mRNA expression in
CRC tissues and found that YAP was inversely corre-
lated with expression of E2A mRNA (r = 0.491, p < 0.01,
Additional file 2: Figure S2), indicating YAP might be
modulated by E2A in a suppressive manner. To find
whether YAP was regulated by E2A, semi-qRT-RCR and
immunoblot were performed to detect the expression of
YAP mRNA and protein level after shE2A, E12 and E47
transfection. As shown in Figure 4A and 4B, YAP
expression was increased both at mRNA and protein
level in SW480/shE2A cells compared with control cells.
Accordingly, both E12 and E47 plasmids attenuated
shE2A-induced increase of YAP expression. Taken to-
gether, YAP was regulated by E2A.
Next, we asked whether the increased YAP in SW480/
shE2A cells led to the enhanced cell aggressiveness. To
this end, transient transfection of shYAP was performed
in SW480/shE2A cells to down-regulate YAP (Additional
file 3: Figure S3). As shown in Figure 4C, compared to
cells transfected with negative control or blank cells, the
invasion and migration ability of SW480/shE2A cells
was significantly reduced by shYAP to the similar levels
as observed in SW480/shNC cells. This finding sug-
gested that the enhanced YAP by shE2A in SW480 cells
was critical in the regulation of cell invasion and migra-
tion. Besides, downregulation of YAP impaired invasion
and migration capacity of SW480 cells (Figure 4D).
More importantly, MMP-9 expression was reduced to
50% of its normal level after shYAP transfection and
changes of EMT markers, i.e. increased expression of
E-cadherin and decreased vimentin, suggested a sup-
pression of this program (Figure 4E). Immunoblot and
immunofluorescence confirmed the expression alterations
of E-cadherin and vimentin after shYAP transfection in
SW480 cells (Figure 4E & F). Conclusively, YAP was atarget through which E2A regulated EMT program to
suppress invasion and migration in CRC cells.
Discussion
Colorectal carcinogenesis is a multistep process mediated
by complex cascades of molecular events governing
genomic stability and cell proliferation [21]. Distant metas-
tases, rather than the primary tumors from which these
lesions arise, are responsible for >90% of carcinoma-
associated mortality [22]. In the present study, we demon-
strated the suppressive role of E2A in colorectal cancer cell
invasion and migration; furthermore, YAP was demon-
strated to be a downstream target of E2A in the metastasis
of CRC cells.
E2A has been well described as a regulator of early B
cell development, and it was dysregulated in lymphoma
and breast cancer [13,23]. Decreased expression of E2A
has been reported in metastatic pancreatic cancer cell
lines [24]. In colorectal adenocarcinomas, ectopic ex-
pression of E47 results in proliferation inhibition [15].
The expression of E2A in CRCs is unknown and its role
in CRC metastasis is also elusive. In this study, for the
first time we investigated the association between E2A
expression and CRC metastasis status and we found
E2A was decreased in CRCs with metastases both at
mRNA and protein levels, indicating its negative relation
to CRC progression. In vitro invasion and migration
assays also supported this: downregulation of E2A
enhanced metastatic capacity of CRC cells while E12
and E47 could offset this effect. Taken together, E2A has
a metastasis suppressive role in CRC. Additionally we
found E2A may exert its action by regulating EMT. The
EMT program plays an important role in tumor progres-
sion and metastasis [18,25]. Loss of epithelial traits and
gain of mesenchymal features make epithelial tumor
cells undergo morphological changes and acquire
enhanced metastatic abilities. In our study, we found E2A
downregulation inhibited the expression of epithelial
marker E-cadherin and increased mesenchymal markers
vimentin and β-catenin in SW480 cells, indicating EMT
suppression by E2A. Considering that E-cadherin was
regulated by multiple signal pathways [26], we speculate
enhanced β-catenin expression was the main reason for
decreased E-cadherin. However, the definite role of E2A
in EMT regulation remains further study.
In further investigating the mechanism of action of
E2A, we found YAP was regulated as a downstream
target. The YAP gene is located on chromosome 11q22,
a region which has been described in previous studies to
be amplified in several types of cancers [27,28]. As one
of the highly conserved components in mammals, YAP
has been proved to be a nuclear effector of the Hippo
pathway and was initially identified by mosaic screens in
Drosophila melanogaster as a vital growth regulator of
Figure 4 Knockdown of YAP attenuates shE2A-induced invasion and migration. A, Downregulation of E2A by shE2A resulted in increased
YAP mRNA expression while transfection of plasmids encoding E12 or E47 decreased YAP mRNA in shE2A treated SW480 cells. B, E2A decreased
YAP protein expression determined by immunoblot analysis. C, YAP knockdown by shYAP in SW480/shE2A cells suppressed the enhanced cell
invasion and migration ability caused by shE2A to a similar level as observed in SW480/shNC cells. D, Downregulation of YAP by shYAP
decreased the invasion and migration ability of SW480 cells. Migration/invasion ability of SW480 decreased after shYAP was transfected into
SW480 cells. Representative photos of stained cells are shown with the original magnification of 100×. Scale bars: 100 μm. E, Immunoblot analysis
of YAP, E-cadherin, vimentin, β-catenin and MMP-9 with GAPDH as loading control. Epithelial marker E-cadherin expression was elevated and
mesenchymal marker vimentin and β-catenin expression was reduced after shYAP was transfected into SW480 cells. MMP-9 was decreased
after shYAP transfection. Data in the histograms is expressed as the means ± SD from 3 separate experiments. F, Representative images of
immunofluorescence analysis of EMT markers. E-cadherin was enhanced while vimentin and β-catenin were decreased after shYAP transfection.
Magnification: 400×; Scale bars: 50 μm. *, P < 0.05; **, P < 0.01.
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transcriptional modulator which has been implicated in
stem cell differentiation, control of organ size, and
tumor growth [32,33]. colonic adenocarcinoma tissues
show up-regulated YAP expression compared with
normal colon tissues, and inducible transgenic expres-
sion of a stabilized YAP mutant (S127A) in mice
induced colonic adenomas [34,35]. Indeed, Wang et al.
found that YAP was a prognostic marker of CRC and
down-regulation of YAP reduced the metastatic ability
of CRC cells [36]. In our study, we found YAP was in-
versely associated with E2A in CRC tissues. This furtherled us to discover that YAP was a downstream target of
E2A as its expression was increased upon shE2A trans-
fection while E12 and E47 transfection could reduce it
to normal level. Moreover, β-catenin, which was regu-
lated by E2A, could enhance YAP expression by directly
binding to YAP gene in CRC cells [37]. In the present
study, we found YAP exerted its function of enhancing
metastasis by inducing EMT in CRC cells, which was in
consistent with the work of Wang et al. [36]. Import-
antly, knockdown of YAP in shE2A treated SW480 cells
could abolish the elevated cell invasion and migration
caused by shE2A. This finding suggested the role of YAP
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migration. Hence, YAP plays as a downstream in mediat-
ing E2A’s function as a tumor suppressive gene in CRC.
Conclusion
The findings of our study suggest that E2A expression is
associated with CRC metastasis. By targeting YAP, E2A
inhibits EMT program and suppresses invasion and
migration in CRC cells. Although E2A’s function in cancer
has not been fully understood, our findings provide new
molecular target and mechanism of action of E2A in CRC
metastasis. Therefore, E2A has the potential value to be
developed as a new target for CRC prevention and
therapy.
Additional files
Additional file 1: Figure S1. E2A suppresses Caco-2 invasion and mi-
gration. A, shE2A expression suppresses invasion and migration of Caco-2
cells. B, E12 or E47 expression decreased cell invasion and migration of
Caco-2/shE2A cells. Data represents the means ± SD from 3 independent
experiments. Representative photos of stained cells are shown with the
original magnification of 100×. Scale bars: 100 μm. *, P < 0.05.
Additional file 2: Figure S2. Significant inverse correlation between
YAP mRNA expression and E2A mRNA expression (Pearson’s correlation
R = −0.491, P < 0.01).
Additional file 3: Figure S3. shYAP decreased the expression of YAP
protein in SW480/shE2A cells. Upper penal: Immunoblot analysis using
anti-YAP antibodies as indicated with or without shYAP expression.
GAPDH was used as loading control. Lower panel: Densitometric analysis
of upper panel normalized to GAPDH.
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